Gene therapies, intelligent drug discovery and development, consumer wearables, telemedicine, and more—what are some of the drivers transforming the life sciences sector? How can biopharma and medtech organizations create new value in 2020, while tackling various challenges? What are the metrics that matter?
The Life Sciences sector is at an inflection point. To prepare for the future and remain relevant in the ever-evolving business landscape, biopharma and medtech organizations will be looking for new ways to create value and new metrics to make sense of today’s wealth of data.
As data-driven technologies provide biopharma and medtech organizations with treasure troves of information, and automation takes over some mundane tasks, new talent models are emerging based on purpose and meaning. The integration of artificial intelligence (AI) and machine learning approaches within life sciences is making drug discovery and development more innovative, time-effective, and cost-effective.
The 2020 Deloitte Global Life Sciences Outlook takes a detailed look at the factors driving these changes and outlines suggestions on how biopharma and medtech organizations can aspire to find real value for themselves and their shareholders in the coming year. It also provides leaders with key questions and actions to consider in the year ahead.
Global life sciences sector issues in 2020
Expolre our previous outlook
Review or download previous life sciences sector outlooks.